他莫昔芬与依西美坦辅助治疗绝经后早期乳腺癌(TEAM):多中心、开放标签、随机、3期试验的10年随访
TEAM试验10年随访纳入原9776例中的6120例绝经后激素受体阳性早期乳腺癌患者,比较依西美坦单药5年与他莫昔芬序贯依西美坦共5年。10年无病生存率两组均为67%(HR 0.96,95%CI 0.88-1.05;P=0.39),长期结果证实两种方案均为合理的辅助内分泌治疗选择。
要点
- 10年无病生存率依西美坦组67% vs 序贯组67%(HR 0.96,95%CI 0.88-1.05;P=0.39)
- 依西美坦组3075例中921例(30%) vs 序贯组3045例中929例(31%)发生无病生存事件
- 长期结果证实依西美坦单药与他莫昔芬序贯依西美坦均为合理的辅助内分泌治疗选择
核心结论
- TEAM试验长期结果证实,依西美坦单药与他莫昔芬序贯依西美坦均为绝经后激素受体阳性早期乳腺癌合理的辅助内分泌治疗选择。
- 这些结果提示,基于患者偏好、合并症和耐受性个体化辅助内分泌策略可能是可行的。
研究设计与样本
- TEAM试验为多中心、开放标签、随机、对照、3期试验,纳入来自九个国家绝经后早期激素受体阳性乳腺癌患者。
- 患者按1:1计算机生成随机排列区组法(区组大小4-8)随机分配至口服依西美坦单药25 mg每日一次持续5年,或口服他莫昔芬20 mg每日一次后序贯依西美坦,总疗程5年。
- 2004年12月13日方案修订后,他莫昔芬组患者在2.5-3.0年后转换为依西美坦治疗,总治疗时长5.0年。
- 当前意向性治疗分析纳入原TEAM试验9776例患者中的6120例,中位随访9.8年(IQR 8.0-10.3)。
- 主要终点为随访10年时的无病生存率。
主要发现
- 随访期间,依西美坦组3075例中921例(30%) vs 序贯组3045例中929例(31%)发生无病生存事件。
- 10年无病生存率依西美坦组67%(95%CI 65-69) vs 序贯组67%(95%CI 65-69)(HR 0.96,95%CI 0.88-1.05;P=0.39)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After 5 years of median follow-up, the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial reported no difference in disease-free survival between exemestane monotherapy and a sequential scheme of tamoxifen followed by exemestane in postmenopausal patients with early-stage, hormone receptor-positive breast cancer. As recurrence risk in hormone receptor-positive breast cancer remains linear beyond 5 years after diagnosis, we analysed long-term follow-up outcomes of this trial. METHODS: The TEAM trial, a multicentre, open-label, randomised, controlled, phase 3 trial, included postmenopausal patients with early-stage hormone receptor-positive breast cancer from nine countries. Patients were randomly allocated (1:1) by a computer-generated random permuted block method (block sizes 4-8) to either 5 years of oral exemestane monotherapy (25 mg once a day) or a sequential scheme of oral tamoxifen (20 mg once a day) followed by exemestane for a total duration of 5 years. After the publication of the IES trial, the protocol was amended (Dec 13, 2004). Patients assigned to tamoxifen were switched after 2·5-3·0 years to exemestane therapy for a total duration of 5·0 years of treatment. Randomisation was done centrally in each country. Long-term follow-up data for disease recurrence and survival was collected in six participating countries and analysed by intention to treat. The primary endpoint was disease-free survival at 10 years of follow-up. The trial is registered with ClinicalTrials.gov, numbers NCT00279448 and NCT00032136; with Netherlands Trial Register, number NTR 267; and the Ethics Commission Trial, number 27/2001. FINDINGS: 6120 patients of the original 9776 patients in the TEAM trial were included in the current intention-to-treat analysis. Median follow-up was 9·8 years (IQR 8·0-10·3). During follow-up, 921 (30%) of 3075 patients in the exemestane group and 929 (31%) of 3045 patients in the sequential group had a disease-free survival event. Disease-free survival at 10 years was 67% (95% CI 65-69) for the exemestane group and 67% (65-69) for the sequential group (hazard ratio 0·96, 0·88-1·05; p=0·39). INTERPRETATION: The long-term findings of the TEAM trial confirm that both exemestane alone and sequential treatment with tamoxifen followed by exemestane are reasonable options as adjuvant endocrine therapy in postmenopausal patients with hormone receptor-positive early breast cancer. These results suggest that the opportunity to individualise adjuvant endocrine strategy accordingly, based on patient preferences, comorbidities, and tolerability might be possible. FUNDING: Pfizer, Dutch Cancer Foundation.
引用
- Derks MGM, Blok EJ, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 28732650. doi:10.1016/S1470-2045(17)30419-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。